盐酸克林霉素棕榈酸酯颗粒剂治疗细菌性感染临床疗效观察

Clinical efficacy of clindamycin palmitate in the treatment of bacterial infections

采用随机对照开放临床试验，对克林霉素棕榈酸酯（ＣＬ－ＰＩ）颗粒剂进行了临床疗效评价，共治疗各种细菌性感染１１２例，其中５０例与盐酸克林霉素（ＣＬ）胶囊随机对照。结果显示随机对照组ＣＬ－ＰＩ和ＣＬ有效率分别为９６．００％（４８／５０）和９６．７２％（５９／６１）（Ｐ＞０．０５），细菌阴转率分别为９１．１１％（４１／４５）和９６．３６％（５３／５５）（Ｐ＞０．０５），均无显著性差异。ＣＬ－ＰＩ开放组治疗感染５０例，有效率为８８．００％（４４／５０），细菌阴转率为９３．６２％（４４／４７）。ＣＬ－ＰＩ单独治疗厌氧菌感染１２例，有效率为８３．３３％（１０／１２），细菌阴转率为９１．６７％（１１／１２），ＣＬ－ＰＩ组总不良反应发生率为１５．１８％（１７／１１２），主要表现为胃肠道反应。个别病人有皮疹，未见肝肾功能损害和伪膜性肠炎的发生。

The clinical efficacies of clindamycin palmitate (CL PI) were observed in a randomized open trial. 100 hospitalized patients with mild or moderate bacterial infections were treated by CL PI. There were also 50 cases in the control group( clindamycin, CL). In the CL PI group, 96.00% of patients were clinically cured or improved, as compared with 96.72% of the patients in the CL group ( P >0.05). The eradication rates of pathogens were 91.11% and 96.36%, respectively ( P >0.05). An additional 50 patients were treated by CL PI in an open trial. 88.00% of patients were clinically cured or markedly improved, and 93.62% of the pathogens were eradicated. 12 patients with anaerobic infections were also treated by CL PI alone. 83.33% of patients were clinically cured or improved, the eradication rates of pathogens were 91.67%. The rate of side effects of CL PI was 15.18% mostly of nausea and drug rashes. No toxic hematologic changes and pseudomembranous colitis, as well as impairment of renal or liver functions occurred.